← Back to Search

Radiation Therapy

Stereotactic Radiosurgery for Malignant Glioma

N/A
Waitlist Available
Led By Alexis M Demopoulos, MD
Research Sponsored by Northwell Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Lobar tumor location (Frontal, temportal, parietal, occipital, or thalamic)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

This trial is testing if a more targeted form of radiation therapy will improve survival for people with malignant gliomas by better targeting cancer stem-like cells.

Eligible Conditions
  • Malignant Glioma
  • Glioblastoma
  • Astrocytoma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Your tumor is located in specific parts of your brain - the front, side, top, back or middle part of your brain.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Toxicity of Therapy
Secondary outcome measures
Progression-free survival

Side effects data

From 2019 Phase 2 trial • 32 Patients • NCT01573702
32%
Fatigue
28%
Lymphocyte count decreased
24%
Cough
20%
Back pain
20%
Rash acneiform
16%
Anorexia
16%
Dry skin
16%
Hyperglycemia
16%
Rash maculo-papular
12%
Aspartate aminotransferase increased
12%
Non-cardiac chest pain
12%
Diarrhea
12%
Dyspepsia
12%
Headache
12%
Nausea
12%
Pain
12%
Pain in extremity
8%
Weight loss
8%
Wheezing
8%
Urinary tract pain
8%
Watering eyes
8%
Arthralgia
8%
Edema limbs
8%
Abdominal pain
8%
Myalgia
8%
Paronychia
8%
Pruritus
8%
Blurred vision
8%
Skin and subcutaneous tissue disorders - Other, specify
4%
Skin infection
4%
Urinary tract infection
4%
White blood cell decreased
4%
Vomiting
4%
Sore throat
4%
Upper respiratory infection
4%
Urinary urgency
4%
Ear pain
4%
Oral hemorrhage
4%
Conjunctivitis
4%
Alkaline phosphatase increased
4%
Blood bilirubin increased
4%
Bone pain
4%
Bruising
4%
Depression
4%
Dry eye
4%
Dysgeusia
4%
Dysphagia
4%
Edema face
4%
Epistaxis
4%
Flashing lights
4%
Flu like symptoms
4%
Gastroesophageal reflux disease
4%
Hot flashes
4%
Hyperkalemia
4%
Hypernatremia
4%
Infusion site extravasation
4%
Insomnia
4%
Lethargy
4%
Nail loss
4%
Nail ridging
4%
Neck pain
4%
Neutrophil count decreased
4%
Papulopustular rash
4%
Platelet count decreased
4%
Pneumonitis
4%
Fracture
4%
Fall
4%
Skin hyperpigmentation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Stereotactic Radiosurgery Followed by Erlotinib

Trial Design

3Treatment groups
Experimental Treatment
Group I: Dose Escalation (22Gy)Experimental Treatment1 Intervention
Receive additional dose of 22Gy to the subventricular zone
Group II: Dose Escalation (20Gy)Experimental Treatment1 Intervention
Receive additional dose of 20Gy to the subventricular zone
Group III: Dose Escalation (18Gy)Experimental Treatment1 Intervention
Receive additional dose of 18Gy to the subventricular zone
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stereotactic Radiosurgery
2016
Completed Phase 2
~460

Find a Location

Who is running the clinical trial?

Northwell HealthLead Sponsor
458 Previous Clinical Trials
470,933 Total Patients Enrolled
Alexis M Demopoulos, MDPrincipal InvestigatorNorthwell Health

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this research still open to qualified participants?

"As observed on clinicaltrials.gov, this research study is not presently accepting enrolment. It was first posted on December 24th 2018 and the details were last updated on February 3rd 2022. Although, there are currently 716 other trials recruiting patients for participation."

Answered by AI
Recent research and studies
~0 spots leftby Mar 2025